AnaptysBio : Presentation (27c0e1)

Published: 2025-06-05 08:56:07 ET ANAB

Published on 06/05/2025 at 08:56

June 2025

Immune Cell Modulators

(PD-1 depleter and agonist)

P2b in

Rheumatoid Arthritis

P2 in Ulcerative Colitis

(CD122 antagonist)

P1 in Healthy Volunteers

(BDCA2 modulator)

P1 in Healthy Volunteers

Autoimmune and inflammatory diseases including dermatology, gastroenterology and rheumatology

Research and Capital

Research-driven

Preclinical pipeline of immunology targets

Strong capital position

Royalty income

Q1 2025 cash: ~$383MM

Expected cash runway: YE 2027

Excludes significant royalty potential:

GSK royalty and milestone potential for Jemperli and cobolimab

GSK $75MM milestone for Jemperli $1B annual WW sales

Vanda royalty and milestone potential for imsidolimab 3

Treaters seek to maximize and sustain remission in maintenance phases

RA: U.S. Market UC: U.S. Market

U.S. sales in b/tsDMARD-experienced market1

U.S. b/tsDMARD patients; 20-25% cycle through all

classes of therapy2

$8bn  >$10bn

U.S. sales in advanced therapy by 20303

~300k and growing

U.S. advanced therapy patients;

Cycling ramping up as advanced therapy market becomes established to avoid surgeries3

Mature, non-growth

market

Established biosimilar 1L SoC (e.g. TNF)

2L access possible, but requires contracting

No new MoA in the last decade

Similarities:

Focus on achieving low disease activity or remissions long-term

1/3 to 1/2 relapse within 1 year following initial response at 3-6 months on induction therapy4

2L+ markets with blockbuster opportunity

Minimal differentiation between biologics

Assess combinations to enhance speed of induction and/or max remission rates

Substantial unmet need for new classes of safe, effective and durable therapies

Dynamic, growing market

1L SoC diversified with growth from branded products (IL-23p19, α4β7)

Minimal payor management of 2L+ therapies

4

1. Expected by 2028 (Evaluate 29 Nov 2022); 2. Market research conducted by Ambit in 2022; 3. Market research conducted by ZS Associates in 2025;

4. Phase 3 registrational data from product labels

Best-in-disease profile through 6 months

•

1

•

JAK-like efficacy in both 3-month placebo-controlled portion and through 6 months

Favorable safety and tolerability, particularly when compared to

standard of care

Monthly (Q4W) dosing

Max response rates have not yet been observed

2

Strict continuation criteria prevented patients with improvement at 3 months from continuing in this P2b trial

Many patients beyond 3 months achieved, or were trending toward, CDAI LDA and ACR50

3

Responses durable after 6 months

Potential for maintenance dosing with extended dosing intervals (e.g. Q8W)

Rosnilimab, a best-in-class depleter and agonist targeting PD-1+ T cells, is well-positioned for the ~$20 billion U.S. RA market

which hasn't had a new mechanism approved since 2012

5

Disclaimer

AnaptysBio Inc. published this content on June 05, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 05, 2025 at 12:55 UTC.